Stock Earnings

Question 1

¿Cuáles son los estados financieros clave de Karyopharm Therapeutics Inc?

Accepted Answer

Según el último estado financiero (Form-10K), Karyopharm Therapeutics Inc tiene un total de activos de $164, una ganancia neta loss de $-76

Question 2

¿Cuáles son los ratios financieros clave para KPTI?

Accepted Answer

El ratio corriente de Karyopharm Therapeutics Inc es 0.46, el margen neto es -52.41, las ventas por acción son $17.84.

Question 3

¿Cómo se desglosan los ingresos de Karyopharm Therapeutics Inc por segmento o geografía?

Accepted Answer

Karyopharm Therapeutics Inc largest revenue segment is Drugs, at a revenue of 145,237,000 in the most earnings release.For geography, United States is the primary market for Karyopharm Therapeutics Inc, at a revenue of 145,237,000.

Question 4

¿Es rentable Karyopharm Therapeutics Inc?

Accepted Answer

no, según los últimos estados financieros, Karyopharm Therapeutics Inc tiene una ganancia neta loss de $-76

Question 5

¿Tiene Karyopharm Therapeutics Inc alguna deuda?

Accepted Answer

yes, Karyopharm Therapeutics Inc tiene una deuda de 350

Question 6

¿Cuántas acciones en circulación tiene Karyopharm Therapeutics Inc?

Accepted Answer

Karyopharm Therapeutics Inc tiene un total de acciones en circulación de 8.41

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Revenue	137	145	146	157	209	108
Revenue Growth (YoY)	-6%	-1%	-7%	-25%	94%	170%
Cost of Revenue	4	6	4	5	3	2
Gross Profit	132	139	141	151	206	105
Selling, General & Admin	110	115	131	145	143	126
Research & Development	136	143	138	148	160	150
Operating Expenses	247	258	270	294	304	277
Other Non Operating Income (Expenses)	31	28	0	0	0	0
Pretax Income	-123	-76	-142	-164	-123	-196
Income Tax Expense	0	0	0	0	0	0
Net Income	-123	-76	-143	-165	-124	-196
Net Income Growth	38%	-47%	-13%	33%	-37%	-2%
Shares Outstanding (Diluted)	8.62	8.12	7.61	5.45	5.01	4.8
Shares Change (YoY)	-16%	7%	40%	9%	4%	16%
EPS (Diluted)	-14.33	-9.4	-18.79	-30.28	-24.74	-40.86
EPS Growth	64%	-50%	-38%	22%	-39%	-15%
Free Cash Flow	-102	-127	-92	-149	-107	-160
Free Cash Flow Per Share	-11.83	-15.63	-12.08	-27.29	-21.33	-33.31
Gross Margin	96.35%	95.86%	96.57%	96.17%	98.56%	97.22%
Operating Margin	-83.94%	-82.06%	-88.35%	-90.44%	-46.88%	-158.33%
Profit Margin	-89.78%	-52.41%	-97.94%	-105.09%	-59.33%	-181.48%
Free Cash Flow Margin	-74.45%	-87.58%	-63.01%	-94.9%	-51.19%	-148.14%
EBITDA	-115	-119	-129	-142	-98	-171
EBITDA Margin	-83.94%	-82.06%	-88.35%	-90.44%	-46.88%	-158.33%
D&A For EBITDA	0	0	0	0	0	0
EBIT	-115	-119	-129	-142	-98	-171
EBIT Margin	-83.94%	-82.06%	-88.35%	-90.44%	-46.88%	-158.33%
Effective Tax Rate	0%	0%	0%	0%	0%	0%

Karyopharm Therapeutics Inc (KPTI) Price

KPTI Stock Price Chart

KPTI Income

Follow-Up Questions